Is Lamisil Worth the Risk? Liver Damage Explained

Terbinafine, sold under the brand name Lamisil, carries a real but uncommon risk of liver injury that most patients will never experience. For the condition it treats best, toenail fungus (onychomycosis), it remains the most effective oral option available, and population-level data suggest its liver-injury rate is among the lowest of all oral antifungals. The question of whether it is “worth it” depends on how severe your fungal infection is, what alternatives exist, and whether you have risk factors that tip the balance.

How Common Is Liver Injury From Terbinafine?

The fear around Lamisil and liver damage is understandable. The drug’s prescribing information includes a boxed discussion of hepatotoxicity, and case reports of serious liver injury get published regularly. But the actual numbers tell a more measured story. A large study of over 90,000 oral antifungal users in Taiwan found that terbinafine had the lowest incidence of drug-induced liver injury among the five antifungals studied: roughly 1.6 cases per 10,000 users. That placed it well below fluconazole (about 31.6 per 10,000), ketoconazole (about 4.9), griseofulvin (about 4.3), and itraconazole (about 3.6).¹ All six fatal cases in that study were associated with fluconazole, not terbinafine.

That said, the risk is not zero, and post-marketing surveillance databases confirm that terbinafine generates a real safety signal for liver injury when used systemically.² The gap between “rare” and “impossible” matters when millions of prescriptions are written each year. Even at 1 to 2 cases per 10,000, a drug used by that many people will produce a meaningful number of injured patients in absolute terms.

What Liver Damage From Terbinafine Actually Looks Like

Terbinafine-related liver injury tends to follow a recognizable pattern. A review of published cases found that symptoms appear, on average, about 30 days after starting treatment, though the range spans from as early as five days to as late as 84 days. The most common symptom is jaundice, the yellowing of skin and eyes. Other frequent signs include flu-like feelings, dark urine, and itching.³ Patients in those cases waited a median of about 16 days after symptoms appeared before seeking medical attention, a delay that could allow the injury to progress.

The injury typically shows a cholestatic pattern, meaning bile flow from the liver is disrupted rather than the liver cells being destroyed outright. In a published case of a 41-year-old man, the damage manifested as worsening jaundice, abdominal pain, itching, and pale stools about two weeks into treatment. Liver biopsy confirmed cholestasis with bile plugs and bile granulomas, with no underlying liver disease to blame.⁴ That cholestatic pattern is important because it tends to be more reversible than outright liver-cell death, though recovery can still take weeks or months after the drug is stopped.

Why Terbinafine Can Hurt the Liver

Terbinafine itself is not the problem. Your liver is. More precisely, the enzymes in your liver that break down terbinafine can produce a reactive byproduct called an allylic aldehyde (TBF-A). Research using both rat and human liver tissue has shown that this metabolite has two chemically “sticky” sites that can latch onto proteins. When the body’s natural detoxifying molecule, glutathione, neutralizes one of those sites, the other can still bind to proteins in the bile ducts.⁵ This protein binding can either directly damage biliary tissue or trigger an immune response that disrupts bile flow, which lines up with the cholestatic pattern seen in clinical cases.

The reason most people tolerate terbinafine just fine is that glutathione and other protective pathways usually mop up the reactive metabolite before it causes trouble. When those defenses are overwhelmed, whether because of individual variation in liver enzyme activity, depleted glutathione stores, or other medications competing for the same pathways, the metabolite gets the upper hand. That is part of why predicting who will be affected is so difficult.

Warning Signs You Should Not Ignore

Because terbinafine liver injury tends to announce itself within the first month or two of treatment, knowing what to watch for can make a real difference. If you develop any of the following while taking terbinafine, contact your prescriber promptly:

• Yellowing skin or eyes: Jaundice is the most common and most visible signal.
• Dark urine: A brownish or tea-colored change suggests bilirubin is spilling into urine.
• Pale or clay-colored stools: This indicates bile is not reaching the intestine normally.
• Persistent itching: Generalized itching without a rash can reflect bile salt accumulation in the skin.
• Upper-right abdominal pain: Discomfort under the rib cage on the right side, where the liver sits.
• Unusual fatigue or nausea: Especially if combined with any of the above.

The data on routine blood monitoring during terbinafine treatment are mixed. Some clinicians order baseline liver function tests and repeat them at four to six weeks, while others argue that monitoring catches injury only after it has already occurred. The review in the British Journal of Dermatology noted that symptoms typically preceded any lab abnormality that would have prompted a clinical visit.³ That does not mean monitoring is useless, but it does mean patient awareness of symptoms is at least as important as scheduled blood draws.

How Effective Terbinafine Really Is

Weighing risk requires knowing the benefit. For toenail onychomycosis, terbinafine’s track record is strong, especially over the long haul. In a five-year blinded follow-up study comparing terbinafine to itraconazole (another common oral antifungal), about 46% of terbinafine-treated patients maintained a clear, fungus-free nail at the end of follow-up without needing retreatment. Only about 13% of itraconazole-treated patients could say the same.⁶ Clinical cure rates showed a similar gap: 42% for terbinafine versus 18% for itraconazole after five years.

A separate large trial, the L.I.ON. study, compared continuous terbinafine to intermittent (pulsed) itraconazole and found mycological cure rates of roughly 76 to 81% for terbinafine versus 38 to 49% for itraconazole at 72 weeks.⁷ For nail fungus specifically, the evidence consistently favors terbinafine as the more effective oral drug.

The picture is different for skin infections. A randomized trial of terbinafine versus itraconazole for skin-based fungal infections found that itraconazole achieved a slightly higher mycological cure rate at four weeks (about 92% versus 74%). Both drugs were well tolerated in that study, with only mild side effects like stomach upset and headache.⁸ So terbinafine’s advantage is most pronounced for nail infections, which are also the ones that typically require longer courses of oral treatment and therefore more cumulative liver exposure.

How Terbinafine Compares to Other Oral Antifungals for Liver Safety

People sometimes assume that switching to a different oral antifungal removes the liver risk. It does not. Every systemic antifungal can cause liver injury. The question is how they stack up against one another. An animal study that compared five common oral antifungals head-to-head found that terbinafine produced lower liver-enzyme elevations than ketoconazole, itraconazole, and fluconazole after 28 days of treatment. On a tissue level, terbinafine also showed less histological damage than fluconazole, ketoconazole, and itraconazole.⁹ Griseofulvin was the only drug that scored slightly better than terbinafine in that experiment.

The human data from the Taiwanese population study mentioned earlier reinforce this ranking. Terbinafine’s incidence of liver injury was the lowest of the five drugs examined.¹ And the same study showed that longer exposure durations increased risk across all drugs. For terbinafine, incidence climbed to about 36 per 10,000 when treatment exceeded 60 defined daily doses, still lower than ketoconazole or itraconazole at similar durations. In practical terms, terbinafine is not uniquely dangerous among oral antifungals; it is probably the safest of the available systemic options for extended use.

What About Topical Treatments and Other Alternatives?

If liver risk is your primary concern, you might wonder whether you can skip oral medication entirely. FDA-approved topical treatments for onychomycosis include efinaconazole, tavaborole, and ciclopirox nail lacquers, along with certain laser approaches.¹⁰ These topical options avoid systemic drug exposure altogether, which eliminates the liver-injury question. The tradeoff is effectiveness. Cure rates for topical antifungals are considerably lower than for oral medications.¹¹

For mild-to-moderate infections that involve less than half the nail plate and do not affect the nail matrix (the growth area at the base), topicals can be a reasonable choice, particularly for patients unwilling or unable to take oral drugs. For more advanced infections, especially those that have thickened or separated the nail from the nail bed, topicals alone rarely clear the fungus. Some dermatologists combine topical therapy with a shorter course of oral terbinafine to reduce cumulative exposure while improving outcomes, though this approach has less standardized evidence behind it.

Choosing the right treatment involves weighing your infection’s severity, your comfort with risk, your budget, and how much the condition affects your daily life. Onychomycosis is not just cosmetic for many people. Thickened, deformed nails can make it painful to wear shoes, can serve as a reservoir for spreading fungal infections to skin and other nails, and in people with diabetes or impaired circulation, can contribute to secondary bacterial infections. Treatment decisions, as one review put it, involve ethical and evidence-based judgment that accounts for each patient’s individual situation.¹⁰

Terbinafine in Older Adults and People With Liver Disease

Because toenail fungus becomes more common with age, a large share of terbinafine prescriptions go to older patients who often take multiple medications. A subgroup analysis from the IRON-CLAD trial looked specifically at older adults and found that the overall adverse-event rate was only modestly higher than in the general study population (28% versus 23%). Most of those events were mild, and only about 4% of the older group discontinued treatment due to side effects. Almost 87% of all reported events were judged unrelated to the drug. Despite the fact that roughly two-thirds of the older subgroup were on blood-pressure medications and a quarter were on diabetes drugs, there were no signs of clinically meaningful drug interactions.¹²

What about people who already have liver disease? Conventional wisdom says terbinafine is off-limits for them. But a case report documented the safe use of oral terbinafine in a 77-year-old woman with stable autoimmune hepatitis. The prescribers took precautions: they consulted the patient’s liver specialist, limited the treatment course to under six weeks, monitored liver tests closely, and educated the patient on warning signs. The fungal infection cleared without any worsening of her liver disease.¹³ One case report does not change a general recommendation, but it illustrates that a blanket prohibition may be overly rigid. When the infection is severe and alternatives are inadequate, a cautious, closely monitored course can be considered in partnership with a hepatologist.

Side Effects Beyond the Liver

Liver injury gets the most attention, but it is not the most common adverse effect of terbinafine. Stomach upset, headache, and rash are far more frequent and usually mild enough that they do not require stopping the drug. One side effect that catches patients off guard is taste disturbance. Some people on terbinafine notice that food tastes muted or metallic.

Objective testing has confirmed this is not just perception. A study that formally measured taste function in terbinafine users found significant decreases in the ability to detect sweet, sour, and bitter tastes across both the front and back of the tongue. Salt taste was also reduced, though only in the back of the tongue. Smell, interestingly, was unaffected.¹⁴ For most people, taste returns to normal within a few weeks of stopping the drug, but rare cases of prolonged or permanent taste loss have been reported. If food starts tasting odd while you are on terbinafine, mention it to your prescriber; it is a known effect, and the decision to continue depends on how far along you are in the treatment course.

Drug Interactions Worth Knowing About

Terbinafine is a strong inhibitor of the liver enzyme CYP2D6, which metabolizes a wide range of other drugs. For most people, this does not cause problems, but there are specific combinations to avoid. The most clinically concerning is the pairing of terbinafine with tamoxifen, a drug used in breast cancer treatment. Tamoxifen relies on CYP2D6 to convert it into its most active form, endoxifen. Blocking that conversion with terbinafine reduces tamoxifen’s effectiveness, which could have serious consequences for cancer treatment.¹⁵

Other medications metabolized by CYP2D6 include certain antidepressants, beta-blockers, and antipsychotics. When terbinafine slows their breakdown, blood levels of those drugs can rise, potentially increasing side effects. If you are on any chronic medications, make sure your prescriber reviews possible interactions before starting terbinafine. The elderly subgroup in the IRON-CLAD trial showed no clinically apparent interactions with common cardiovascular and diabetes drugs, which is reassuring for many of the most frequently co-prescribed medications.¹² But tamoxifen is a hard no.

The Reinfection Problem

Even when terbinafine works perfectly and the nail clears, the fight may not be over. Onychomycosis has notoriously high reinfection and recurrence rates.¹⁰ A cleared nail does not mean your feet are now immune to fungus. The same warm, damp environments that caused the original infection (communal showers, sweaty shoes, shared nail clippers) will happily deliver a new one. And toenails grow slowly, so even if reinfection happens shortly after treatment ends, you may not notice it for months.

This matters for the risk-benefit calculation. If you are likely to need repeated courses of oral antifungal treatment over the years, your cumulative liver exposure increases. Longer exposure durations are associated with higher rates of liver injury across all oral antifungals.¹ Preventive habits such as keeping feet dry, rotating shoes, treating athlete’s foot promptly before it reaches the nails, and avoiding barefoot walking in high-risk areas become part of the treatment strategy, not just afterthoughts. Addressing the environment that feeds the fungus is what turns a single successful course of terbinafine into a lasting result.

When Terbinafine Makes Sense and When It Might Not

Terbinafine is most clearly justified when you have moderate-to-severe toenail onychomycosis caused by a dermatophyte, the group of fungi it targets best. It is the most effective oral drug for that specific job, with the lowest liver-injury incidence among systemic antifungals. For skin-only fungal infections that might respond to topical creams or shorter courses of other drugs, the risk-benefit math shifts because the infection is easier to treat without systemic medication.

Situations where extra caution or an alternative approach is warranted include active liver disease or a history of drug-induced liver injury, concurrent use of tamoxifen or other CYP2D6-sensitive medications where reduced efficacy could be dangerous, and mild nail infections that might respond to topical therapy alone. For people in these categories, a conversation with a dermatologist and possibly a hepatologist is worth having before committing to three months of oral terbinafine. For the majority of patients with significant toenail fungus and no specific contraindications, the evidence suggests the liver risk, while real, is small enough that the drug’s proven effectiveness makes it a reasonable choice.